Diagnostic and therapeutic methods for sarcomatoid kidney cancer

A therapy, sarcoma technology, applied in the field of diagnosis and treatment of sarcomatoid renal cell carcinoma, which can solve problems such as difficulty in detection and treatment

Pending Publication Date: 2021-07-30
F HOFFMANN LA ROCHE & CO AG
View PDF171 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite significant advances in the medical treatment of some cancers, the 5-year overall survival rate for all cancers has only improved by about 10% over the past 20 years
In particular, malignant solid tumors metastasize and grow rapidly in an uncontrolled manner, making timely detection and treatment extremely difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic and therapeutic methods for sarcomatoid kidney cancer
  • Diagnostic and therapeutic methods for sarcomatoid kidney cancer
  • Diagnostic and therapeutic methods for sarcomatoid kidney cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0656] Example 1: Sarcomatoid Histology, MSKCC Risk Score, and Molecular Correlations Differentiate Response to Atezolizumab + Bevacizumab vs. Sunitinib: Stage III of Untreated Metastatic Renal Cell Carcinoma Research (IMmotion151) Results

[0657] The IMmotion151 study (ClinicalTrials.gov identifier NCT02420821) is a multicenter, randomized, open-label study evaluating atezolizumab in combination with bevacizumab and sunitinib in patients with inoperable, locally advanced, or metastatic disease Efficacy and safety in patients with sexual RCC who have not received prior systemic active or experimental therapy in the adjuvant or metastatic setting. see figure 1 . The co-primary endpoints of the study were PFS in the PD-L1+ subgroup and OS in the ITT population. Exploratory endpoints included biomarker characterization in sarcoid-like tumors and MSKCC risk subgroups, as well as validation of gene signatures from the IMmotion150 study and association of gene signatures with PF...

example 2

[0669] Example 2: Atezolizumab + Bevacizumab vs Sunitinib in Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Histology: IMmotion151 Subgroup Analysis

[0670] As described in Example 1, renal cell carcinoma (RCC) with sarcomatoid histology is characterized by the presence of spindle-shaped malignant lesion epithelial cells. Sarcomatoid histology is associated with multiple histological subtypes of RCC and confers an aggressive phenotype. Patients with metastatic RCC with sarcomatoid histology (approximately 10%-20% of patients with advanced disease) have a particularly poor prognosis and have a limited response to vascular endothelial growth factor pathway inhibition. Here, we report the results of a prespecified subgroup analysis to assess the efficacy of atezolizumab plus bevacizumab versus sunitinib in IMmotion151-enrolled patients with sarcoid histology and explore Biological correlates of sarcomatoid and non-sarcomatoid histology.

[0671] method...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., kidney cancer (e.g., renal cell carcinoma (RCC)). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a VEGF antagonist (e.g., an anti-VEGF antibody, (e.g., bevacizumab) or a VEGFR inhibitor (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib))) and a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)), or with an angiogenesis inhibitor (e.g., a VEGF antagonist (e.g., a VEGFR inhibitor, (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib)))).

Description

[0001] sequence listing [0002] This application contains a Sequence Listing, which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy was created on October 8, 2019, named 50474-191WO3_Sequence_Listing_10.8.19_ST25, and is 235,579 bytes in size. technical field [0003] The present invention relates to diagnostic and therapeutic methods for the treatment of cancer (eg, kidney cancer). Background technique [0004] Cancer remains one of the deadliest threats to human health. Cancer affects nearly 1.3 million new patients each year in the United States and is the second leading cause of death after heart disease, accounting for about a quarter of all deaths. It can also be predicted that within 5 years, cancer may surpass cardiovascular disease as the leading cause of death. Solid tumors are the leading cause of these deaths. Despite major advances in medical treatment of some cancers, the 5-year ove...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/574A61K39/00
CPCG01N33/57484G01N33/57438G01N2800/52A61K2039/868C07K16/22C07K16/2827A61P35/00A61K39/39558A61K2039/507A61K31/404A61K31/4439A61K31/506A61K31/47A61K2300/00C07K2317/56A61K45/06G01N2496/00
Inventor C·席夫M·格林M·哈瑟尼
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap